Skip to main content

Moderna vs Pfizer: Revenue, Profit and Business Model

Moderna had $1.9B of annual revenue in FY2025 and a net loss of $2.8B. Pfizer had $62.6B of annual revenue in FY2025 and $7.8B of net income.

Latest financial snapshot

Moderna

Latest annual revenue
$1.9B (FY2025)
Net income
-$2.8B
Net margin
-145.2%
Revenue growth
+37.8% a year, FY2016–FY2025

Pfizer

Latest annual revenue
$62.6B (FY2025)
Net income
$7.8B
Net margin
12.4%
Revenue growth
+1.9% a year, FY2016–FY2025

Financial summary

Moderna

Moderna went from $803 million of revenue in 2020 to $18.5 billion in 2021 and $19.3 billion in 2022, earning $12.2 billion and $8.4 billion of net income in those years. Revenue then fell to $6.8 billion in 2023, $3.2 billion in 2024 and $1.94 billion in 2025, with net losses of $4.7 billion, $3.6 billion and $2.8 billion. In 2025 Moderna cut operating expenses by about $2.2 billion (roughly 30%) and ended the year with $8.1 billion in cash and investments. Q2 2026 revenue was $145 million with a $782 million net loss; management guided to up to 10% revenue growth for 2026 and cash costs of about $4 billion. Moderna, Inc. is a major American pharmaceutical and biotechnology company pioneering messenger RNA (mRNA) therapeutics, sustaining a market valuation typically over $40 billion.

Pfizer

Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.

Revenue and profit by year

Moderna

Moderna revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$1.9B-$2.8B-145.2%-39.9%Source
FY2024$3.2B-$3.6B-110.0%-52.7%Source
FY2023$6.8B-$4.7B-68.8%-64.4%Source
FY2022$19.3B$8.4B43.4%+4.3%Source
FY2021$18.5B$12.2B66.1%+2200.2%Source
FY2020$803M-$747M-93.0%+1233.7%Source
FY2019$60.2M-$514M-853.7%-55.4%Source
FY2018$135.1M-$384.7M-284.8%-34.4%Source
FY2017$205.8M-$255.9M-124.3%+89.9%Source
FY2016$108.4M-$216.2M-199.5%—Source
Full Moderna financials

Pfizer

Pfizer revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$62.6B$7.8B12.4%-1.6%Source
FY2024$63.6B$8B12.6%+6.8%Source
FY2023$59.6B$2.1B3.6%-41.1%Source
FY2022$101.2B$31.4B31.0%+24.5%Source
FY2021$81.3B$22B27.0%+95.2%Source
FY2020$41.7B$9.2B22.0%+1.8%Source
FY2019$40.9B$16B39.2%+0.2%Source
FY2018$40.8B$11.2B27.3%-22.3%Source
FY2017$52.5B$21.3B40.6%-0.5%Source
FY2016$52.8B$7.2B13.7%—Source
Full Pfizer financials

Where the revenue comes from

Moderna

  • Product SalesPrimary

    Commercial sales of Moderna's mRNA vaccines, led by COVID and RSV products.

  • Collaboration Revenue

    Complementary

    Revenue from development collaborations, partner programs, and shared pipeline work.

  • Grants And Other Revenue

    Complementary

    Government, nonprofit, and other support tied to vaccine and platform development.

  • Future Pipeline Commercialization

    Potential

    Revenue potential from respiratory combinations, oncology, rare disease, and other mRNA medicines if approved.

Pfizer

  • Patented medicines

    Core revenue

    Prescription drugs protected by exclusivity and clinical differentiation.

  • Vaccines

    Major revenue contributor

    Adult, pediatric, pneumococcal, RSV, and COVID-related vaccines.

  • Oncology

    Strategic growth driver

    Cancer medicines, antibody-drug conjugates, and Seagen-related assets.

  • Hospital and anti-infective products

    Meaningful contributor

    Sterile injectables, anti-infectives, and hospital therapies.

  • Collaborations and alliances

    Supplemental

    Co-promoted products and partnered scientific platforms.

Business model and strategy

Moderna

How it makes money

Moderna earns most of its revenue from net product sales of mRNA vaccines: Spikevax and mNEXSPIKE for COVID-19, mRESVIA for RSV, and from the 2026-2027 season mFLUSIVA for influenza. Buyers are governments, national immunization programs, pharmacy chains, wholesalers and health systems, so sales are concentrated in the autumn and winter vaccination season.

Growth strategy

Moderna is narrowing its pipeline to programs with near-term commercial potential: respiratory vaccines (COVID, RSV, flu and combinations), individualized cancer therapy with Merck, and a small set of rare-disease and latent-virus programs.

Competitive advantage

Moderna's advantages are a validated mRNA and lipid nanoparticle platform, a large patent estate on modified mRNA, in-house manufacturing in Norwood, Massachusetts plus onshore plants in the UK, Canada and Australia, and regulatory experience across approved respiratory products.

Moderna business model in full

Pfizer

How it makes money

Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology.

Growth strategy

Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total).

Competitive advantage

Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities.

Pfizer business model in full

Questions about Moderna vs Pfizer

Which company has higher revenue — Moderna, Inc. or Pfizer Inc.?

Moderna, Inc. had $1.9B (FY2025), while Pfizer Inc. had $62.6B (FY2025). By latest annual revenue, Pfizer Inc. is the larger business, with Moderna, Inc. showing a smaller revenue base.

What is the market cap of Moderna, Inc. vs Pfizer Inc.?

Moderna, Inc.'s market capitalisation stands at $72.7B, while Pfizer Inc.'s is $160.3B. Pfizer Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Moderna, Inc..

How does revenue per employee compare for Moderna, Inc. and Pfizer Inc.?

Moderna, Inc. has $414k / employee in revenue per employee, while Pfizer Inc. has $834k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do Moderna, Inc. and Pfizer Inc. make money?

Moderna, Inc. and Pfizer Inc. generate revenue in fundamentally different ways. Moderna, Inc.: Moderna earns most of its revenue from net product sales of mRNA vaccines: Spikevax and mNEXSPIKE for COVID-19, mRESVIA for RSV, and from the 2026-2027 season mFLUSIVA for influenza. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.

Which company is valued higher relative to revenue — Moderna, Inc. or Pfizer Inc.?

On a price-to-sales (P/S) basis, Moderna, Inc. trades at 37.4x P/S and Pfizer Inc. at 2.6x P/S. Moderna, Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Pfizer Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is Moderna, Inc. bigger than Pfizer Inc.?

By last reported revenue, Pfizer Inc. ($62.6B (FY2025)) is the larger company compared to Moderna, Inc. ($1.9B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Moderna vs Pfizer overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.